#United States #New York #Gross Law Firm #ESSA Pharma #EPIX

Investors of ESSA Pharma Inc. Urged to Join Class Action Lawsuit for Shareholder Protection

ESSA Pharma Inc. Investors: Important Class Action Alert

The Gross Law Firm has announced an important notice for shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). A class action lawsuit has been filed, focusing on securities violations that occurred between December 12, 2023, and October 31, 2024. If you purchased shares during this window, it is crucial to be aware of the upcoming deadlines and your potential role in this legal action.

Background of the Case

This class action lawsuit arises from allegations concerning the misleading statements made by ESSA Pharma relating to their product, masofaniten, used in conjunction with enzalutamide for treating prostate cancer. The claims in the lawsuit detail how the company allegedly overstated the drug's efficacy and commercial prospects. Specifically, the complaint notes that:

1. Misleading Efficacy Claims: It was claimed that masofaniten combined with enzalutamide provided significant benefits over enzalutamide alone when, in fact, no clear efficacy advantage existed.
2. Clinical Trial Outcomes: The lawsuit outlines that the M-E Combination Study was unlikely to meet its anticipated Phase 2 primary endpoint, contrasting the company's prior assertions.
3. Impact on Shareholders: As a result of these and other misstatements, shareholders may have faced significant losses, as the company's stock was artificially inflated due to false information.

Deadline for Lead Plaintiff Appointment

The firm has established a deadline of March 25, 2025, for shareholders to register if they wish to be considered for the position of lead plaintiff. This position does not require you to be enrolled in the recovery process but offers an avenue for shareholders looking to take a proactive role in the litigation.

It is strongly advised for shareholders affected by this situation to register as soon as possible. The firm will provide ongoing updates throughout the case's lifecycle, ensuring you remain informed of any developments.

Why Join this Class Action?

Participating in this class action provides affected shareholders the opportunity to reclaim losses stemming from the alleged economic damages associated with the company’s misleading actions. By registering, you will automatically be enrolled in a portfolio monitoring service, keeping you updated about the case's status without incurring any fees or obligations.

The Gross Law Firm is recognized for its commitment to securities law protection, making their participation in this case significant. They focus on safeguarding investor rights and ensuring accountability for corporate actions that lead to financial harm.

Next Steps for Affected Shareholders

If you purchased shares of ESSA Pharma during the class period, you can register your interest in the lawsuit through the link provided here: Registration Link. This action will secure your place in the case and facilitate potential recovery of your losses.

In summary, it is essential for ESSA Pharma investors to act swiftly. The impending deadline for lead plaintiff registration is just around the corner, and engaging with the Gross Law Firm can safeguard your investments against corporate misconduct. Stay proactive and informed to protect your shareholder rights.